Alligator Bioscience AB is a Sweden-based pharmaceutical company specializing in the development of immune activating antibody drugs for tumor-directed immunotherapy. With an ESG score of 28.5, the company is assessed as having a medium risk. Alligator Bioscience AB is committed to environmental sustainability and good governance practices in the pharmaceutical industry. Their product portfolio includes ADC-1013, ATOR-1015, and ATOR-1016, paving the way for innovative cancer treatments. Discover the cutting-edge advancements in ESG-focused immunotherapy with Alligator Bioscience AB.